Market Announcement

2 June 2020

PharmAust Limited (ASX: PAA) – Suspension from Official Quotation

Description

The securities of PharmAust Limited ('PAA') will be suspended from quotation immediately under Listing Rule 17.2, at the request of PAA, pending the release of an announcement regarding disclosure of preliminary results from a pre-clinical trial.

Issued by

Sandra Wutete
Sandra Wutete, Listings Compliance (Perth)

2 June 2020

Mr Dale Allen
Australian Securities Exchange
Level 40, Central Park
152-158 St Georges Terrace
PERTH WA 6000

Dear Mr Allen,

REQUEST FOR VOLUNTARY SUSPENSION

PharmAust Limited (ASX: PAA) hereby requests a voluntary suspension be placed on the Company's securities pending an announcement regarding disclosure of preliminary results from the SARS-CoV-2 pre-clinical trial.

The Company requests that the voluntary suspension will remain in place until such time that the Company can release the announcement which is expected to be 3 June 2020.

The Company is not aware of any reason why the voluntary suspension should not be granted, nor of any other information necessary to inform the market about the voluntary suspension.

Yours sincerely,

Sam Wright
Finance Director